While alcohol use on a GLP-1 may be okay, the choice carries some theoretical risks, including reduced weight loss potential and possibly worsened side effects of GLP-1s
For these individuals, a modified approach may be appropriate
For patients with serious comorbidities that aren't responding sufficiently to medication, this can be life-changing
The primary endpoint is a renal composite episode defined by a decrease in GFR 50%, end-stage renal failure, and death from a renal-cause or cardiovascular-caused death, and it is scheduled for completion in 2024
However, dose adjustments are not usually needed in patients with kidney disease
Particularly, individuals on medications that lower blood sugar could face a heightened risk of hypoglycemia